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ABSTRACT 
SIMULA TION STUDY FOR THE LEAD TIME IN CANCER SCREENING WHEN 
HUMAN LIFETIME IS A COMPETING RISK 
Sarah K. Kendrick 
April 16,2013 
PURPOSE: The purpose of this paper is to examine the lead time distribution in 
cancer screening trials when lifetime is a random variable in order to determine optimal 
initial age at screening and screening frequency. METHODS: Simulation was used in 
order to estimate the distribution of the lead time for a hypothetical individual with a 
future screening schedule. The lifetime distribution used comes from the Social Security 
Administration's actuarial life tables. The lead time distribution was then calculated 
based on two different sojourn time distributions (log-logistic and exponential) with four 
mean sojourn times (2, 5, 10, and 20 years), using three different initial screening ages, 
to=40, 50, 60, and four different screening frequencies, every six months, every year, 
every 1.5 years, and every two years for both males and females. RESULTS: Smaller 
time intervals between screenings yield a smaller probability of no benefit and a greater 
expected lead time. 
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INTRODUCTION 
Cancer has been sweeping the nation in recent history, and there has been a lot of 
research on cancer treatments and effective screening for cancer. Among men, prostate 
cancer is the most common cancer followed by lung cancer and colorectal cancer with 
lung cancer being the leading cause of cancer death in men followed by prostate cancer. 
For women, the most prevalent cancers are breast cancer, followed by lung cancer, and 
then colorectal cancer with lung cancer being the leading cause of cancer death, followed 
by breast cancer (Centers for Disease Control and Prevention, 2009). 
Each type of cancer has a different screening methodes) used for early detection 
which could lead to a better prognosis. Prostate cancer has two different screening 
methods, a digital rectal exam (DRE) and a prostate specific antigen test (PSA). 
However, the United States Preventative Services Task Force does not recommend 
getting the PSA test for men who are asymptomatic (U.S. Preventative Services Task 
Force, 2012). Screening options for breast cancer consist of self exams, mammograms, 
and clinical breast exams. Lumps and changes in size or shape of the breast(s) or 
underarm are warning signs for breast cancer, and are usually detected by self or clinical 
examination (examination by a nurse or doctor). Even though these two methods can be 
helpful in detecting breast cancer, they have not been shown to decrease one's risk of 
1 
death from breast cancer. However, getting regular mammograms, an X-ray of the 
breasts, has been shown to decrease an individual's risk of death due to breast cancer 
(Centers for Disease Control and Prevention, 2012). Screening options for lung cancer 
include chest X-rays, sputum cytology, and CT scans but there is debate over whether 
any of these actually help in decreasing deaths from lung cancer (Centers for Disease 
Control and Prevention, 2011). Colorectal cancer, liver cancer, and all other cancers have 
screening testes) just as the cancers mentioned above. Screening is more beneficial in 
some cancers, such as breast cancer, than others, such as lung cancer. 
The most common model for the progression of cancer is one occurring in three 
stages: So, Sp, and Sc (ZELEN & FEINLEIB, 1969). So is known as the disease-free state, 
Sp is the preclinical state in which the individual has developed the disease, and can be 
detected by screening, but has shown no clinical symptoms, and Sc is the clinical state in 
which the individual exhibits clinical symptoms. The difference in time between the age 
at which an individual enters the preclinical state and the age the individual begins to 
experience clinical symptoms (tc-tp where tc>tp) is defined as the individual's sojourn 
time. If disease was detected by screening after the individual entered the preclinical 
state, but prior to experiencing any symptoms, the time difference between the age at 
detection by screening and the age at onset of symptoms is referred to as the individual's 
lead time. 
The topic of lead time has been an area of much research over the past 20 to 30 
years. Many studies have worked to determine the parameters, formulas, and distributions 
that most accurately estimate the important descriptive statistics for the lead time 
distribution, such as mean and variance. One of the largest contributions to the topic of 
2 
lead time was the work done by Prorok in 1982. Prorok's goal was to determine the 
optimal number of screenings required for effective and efficient evaluation in repetitive 
screening trials. He used the lead time properties of screen detected cases to develop a 
stopping rule for these kinds of studies. What he found was that the lead time tended to 
stabilize after four to five screenings when the screening frequency was held constant. 
This property showed that any screenings in excess of the fourth or fifth one may no 
longer provide any additional information. However, Prorok's design contained one 
major hole: he did not take interval cases, where lead time is zero, into account (Prorok, 
1982). Wu et al. (2007) took the method proposed by Prorok a little further. They 
included both screen-detected cases, and interval cases in order to derive the probability 
distribution function for the lead time, and used Prorok's results in their model as a 
special case - where there are no interval cases. However, Wu et al. (2007) derived the 
lead time distribution while assuming that lifetime is a fixed value, which is unrealistic. 
Then, in 2012, Wu et al. extended their previous method to the case where lifetime is 
subject to competing risks, and is, therefore, a random variable. 
In this paper we will extend the research done by Wu, Kafadar, Rosner, and 
Broemeling in 2012. We will look at the lead time distribution for several different 
screening situations in order to gain an understanding of how/if screening is beneficial for 
different cancers. We will look at three hypothetical cohorts of initially asymptomatic 
men and women. The three cohorts will be based on initial age at screening: 40, 50, and 
60 years old. Within each cohort we will examine the effect of four different screening 
frequencies on the lead time distribution: delta = 6 months, one year, one and a half 
years. and two years. We will also look at two different distributions for the sojourn time: 
3 
log logistic and exponential. Our results will give insight into the benefits of screening 




Lead Time Distribution when Lifetime is Fixed 
This study used simulation data to determine the lead time distribution for a 
hypothetical cohort of initially asymptomatic individuals with no history of cancer. First 
we must define some variables and notation. Let t be the age of the individual at a 
screening exam, to be the age at which the individual has their initial screening, T be the 
individual's lifetime, L indicate the lead time, D be a binary random variable using D=1 
to indicate disease development and 1)=0 to indicate no disease, and K be the total 
number of screenings the individual will undergo in their lifetime. Now we let f3(t) be the 
sensitivity of the screening modality and define w(t)dt as the probability that an 
individual will transition from the disease-free state(So) to the preclinical state (Sp) during 
the interval (t, t+dt); q(x) as probability distribution function of the sojourn time, and 
Q(z) = Jzoo q(x)dx as the survivor function for the sojourn time. From the Health 
Insurance Plan for Greater New York (HIP) study we know that f3(t) was characterized 
using a logistic model, 
1 
(J(t) = -------
1 + exp { - bo - b1 (t - f)} 
Where f=the average age at entry. The transition density function is that of a log normal 
(11, ()2) density function multiplied by 0.2, the upper limit of lifetime risk, 
5 
2 0.2 {(109t - 11)2} 
w(tll1, a ) = r-c exp - 2 2 ' a > O. 
v 2Trat a 
Finally, we will use the log logistic and the exponential distributions to define the sojourn 
time distribution. This yields the following survivor and hazard functions: 
1. Log logistic 
1 
Q(x) = 1 + (Xp)K 
2. Exponential 
KXK-lpK 
and hex) = 1 + (Xp)K' K > 0, P > 0, and 
Q(x) = e- itx and hex) = A. 
We then combine these two functions to define the density function for the sojourn time: 
q(x) = h(x)Q(x), where x is the sojourn time. The above equations contain the following 
unknown parameters, bo, bl, /1, (i, K, and p (Wu, Rosner, & Broemeling, 2005). 
Each individual undergoes a set of K screening exams during their lifetime at the 
ages of to<tl <t2<' .. <tK-I. For the sake of simplicity we let T=tK even though there is no 
screening at age T. We now look at the distribution oflead time when lifetime is a fixed 
value. As we mentioned in the introduction, lead time consists of two parts: a point mass 
at zero, peL = OlD = 1, T = tK ), indicating an interval case, and a continuous 
conditional probability distribution function, fL(ziD = 1, T = tK)' 
We show that: 
peL = O,D = liT = t K ) 
peL = OlD = 1, T = t K ) = P( _ IT _ ) , D - 1 - tK 
Where 
6 
ftK It Ito = w(x)q(t - x)dxdt = w(x) [Q(to - x) - Q(tK - x)]dx ~ 0 0 
f
tK 
+ w(x) [1 - Q(tK - x)] dx 
to 
And 





fL (z, D = liT = t K) = Po 0 w(x)q(to + z - x)dx 
Or 
fL(z,D = liT = t K ) 
~j-l {~i-l ftr 




w(x)q(ti + z - x)dx 
f
t. } l~ + ti~l w(x)q(ti + z - x)dx + Po 0 w(x)q(to + z - x)dx 
if tK - tj < z :::;; tK - tj-1,j = 2,3, ... , K 
We can prove the validity of this probability by confirming that 
(Wu, Rosner, & Broemeling, 2007). 
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The Lifetime Distribution 
In order to find the distribution of lifetime, we used the actuarial table provided 
by the Social Security Administration. This life table provides information on the 
probability of mortality, the conditional probability of death within one year (P(T < 
N+ liT 2: N)), and life expectancy for both men and women, N=O, 1, 2, ... ,119. It is 
produced using data from all Social Security populations which is comprised of residents 
of the United States and the District of Columbia, civilian residents of U.S. territories, 
civilian Federal employees, individuals in the U.S. Armed Forces abroad and their 
dependents, and all other U.S. citizens (Social Security Administration, 2012). 
To obtain the distribution for the lifetime, some derivations are needed first. If we 
let bN = PCT < N + liT 2: N) and let aN = 1 - bN = PCT 2: N + liT 2: N), then using 
the conditional probability formula we find that, 
PCT 2: N + 21T 2: N) = PCT 2 N + 2, T 2: N + liT 2: N) 
= PCT 2: N + liT 2: N)PCT 2: N + 21T 2: N + 1, T 2: N) = aNaN+l 
Now we can use mathematical induction to apply this concept to any integer age, to, 
N 
PCT 2: to + NIT 2: to) = n PCT 2: to + ilT 2: to + i - 1) 
i=l 
N 
= n ato +i-l '<IN = 1,2, ... ,120 - to· 
i=l 
Next, we use a density approximation for frCt = to + NIT 2: to), 
fTCt = to + NIT 2: to) = lim PCto + N < T ::;; to + N + E IT 2: to) 
1' ..... 0 
8 
N 
= C1 - atO+N) n a to +i-l· 
i=l 
In this case, where N<120, we will use a step function to approximate fTCtIT ~ to) to be 
;;::: fTCNIT ~ to) for any real number tin [N, N+ 1]. Finally, we can show the validity of 
this probability distribution approximation: 
120-to 
L fTCto + NIT ~ to) 
N=O 
120-to 
= L [PCT ~ to + NIT ~ to) - PCT ~ to + N + liT ~ to)] 
N=O 
(Wu, Kafadar, Rosner, & Broemeling, 2012). 
We now use these results to plot the conditional lifetime distributions for men and 
women with initial screening ages of 40, 50, and 60. We must note that this does not take 
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Figure 1. Conditional lifetime distributions for initial screening ages of 40, 50, and 60. 
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Lead Time Distribution When Lifetime is a Random Variable 
Using the ideas and formulas when lifetime was a fixed number, we can 
determine the distribution of the lead time when lifetime is a random variable by 
implementing a few modifications. When lifetime is a random variable, the number of 
screenings an individual will receive in their lifetime is also variable and is a function of 
their lifetime, K=k(T) where K is the largest integer that satisfies tK-l < T. To obtain the 
distribution of the lead time when lifetime is a random variable we define the following, 
peL = DID = 1, T ;::: to) = LXlP(L = DID = t, T = t)fT(tIT ;::: to)dt 
to 
fL(ziD = 1, T;::: to) = LXl fL(ziD = 1, T = t)fT(tIT;::: to)dt z E (0,00) 
to+Z 
The lower bound in the above equation is (to+z) instead of to since the lead time should be 
less than t-to, therefore, t should be greater than to+z. The equations 
peL = DID = t, T = t) and fL(ziD = 1, T = t) come from the situation where lifetime is 
a fixed value and the conditional distribution of the lifetime is, 
fT(t) 
otherwise. 
We can show that the equations above are a valid mixed probability distribution: 
11 
peL = OlD = 1, T :;::: to) + {"'fL (ziD = 1, T :;::: to)dz 
= lCX) peL = OlD = 1, T = t)fT(tIT :;::: to)dt 
to 
+ fOO foo fL (ziD = 1, T = t) fT(tiT :;::: to)dtdz 
o to+Z 




+ Jr fL(ziD = 1, T = t) fTCtIT :;::: to)dtdz 
to 0 
(Wu et aI., 2012). 
12 
RESULTS 
We can apply the above methods to any screening schedule. For our example we 
will consider three different initial screening ages for both men and women ofto=40, 50, 
and 60. For each initial age we will examine the effects of four different screening 
frequencies, L1=0.5, 1.0, 1.5, and 2.0 years. Finally, for each combination of initial 
screening age and screening frequency we will consider the case where the sojourn time 
has a log-logistic distribution and the case where it has an exponential distribution. The 
following tables give the probability of no benefit (lead time equal to zero), for each 
initial screening age, screening frequency, and sojourn time distribution combination as 
well as the estimate for the probability of benefit, the expected lead time, and the median 
lead time (for females only since the results are very similar for males and females). 
13 
Table 1 




c Medd ph 0 I-Po EL
c Medd 
Initial Screening Age to=40 
6 Months 28.40 71.60 0.533 2.9 32.26 67.74 0.745 2.9 
12 Months 44.94 55.06 0.453 2.7 43.02 56.98 0.684 2.7 
18 Months 52.87 47.13 0.380 2.8 51.58 48.42 0.627 2.8 
24 Months 63.68 36.32 0.324 2.7 58.59 41.41 0.578 2.7 
Initial Screening Age to=50 
6 Months 8.34 91.66 1.42 1.9 14.23 85 .77 1.69 1.9 
12 Months 24.10 75 .90 4.20 1.8 24.87 75.13 1.52 1.8 
18 Months 39.97 60.03 1.01 1.8 33.54 66.46 1.55 1.8 
24 Months 52.71 47.29 0.861 1.7 40.76 59.24 1.42 1.7 
Initial Screening Age to=60 
6 Months 5.40 94.6 1.92 1.7 11.32 88.68 2.41 1.9 
12 Months 19.56 80.44 1.63 1.6 20.80 79.2 2.21 1.9 
18 Months 34.32 65 .68 1.37 1.6 28 .77 71.23 2.02 1.9 
24 Months 46.32 53.68 1.18 1.6 35.51 64.49 1.86 1.9 
a Time between screenings (ti - ti-l) 
b Po = P(L=OID= l) = Probability of no early detection (%) 
C The mean lead time is in years 
d The median when L > 0 (for non-interval cases) 
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Table 2 
A projection of the lead time distribution when mean sojourn time = 5 years 
Log-Logistic Exponential 
8. Po I-Po EL Med Po I-Po EL Med 
Initial Screening Age to=40 
6 Months 18.15 81.85 1.44 4.3 23.55 76.45 1.22 4.7 
12 Months 20.48 79.52 1.42 4.1 29.40 70.60 1.20 4.5 
18 Months 23.06 76.94 1.38 3.9 34.25 65.75 1.18 4.4 
24 Months 26.18 73.82 1.35 3.8 38.50 61.5 1.16 4.2 
Initial Screening Age to=50 
6 Months 7.35 92.65 3.3 1 3.1 7.47 92.53 2.79 3.0 
12 Months 20.87 79.13 3.25 2.8 l3.25 86.75 2.73 2.9 
18 Months 34.43 65.57 3.16 2.6 18.32 81.68 2.66 2.9 
24 Months 45.31 54.69 3.07 2.4 22.91 77.09 2.59 2.8 
Initial Screening Age to=60 
6 Months 0.304 99.696 4.14 2.7 4.79 95.21 3.60 2.4 
12 Months 1.43 98.57 4.08 2.6 9.20 90.8 3.52 2.4 
18 Months 3.42 96.58 3.99 2.5 13.29 86.71 3.43 2.4 
24 Months 6.15 93.85 3.89 2.4 17.08 82.92 3.36 2.4 
Table 3 
A projection of the lead time distribution when mean sojourn time = 10 years 
Log-Logistic Exponential 
8. Po I-Po EL Med Po I-Po EL Med 
Initial Screening Age to=40 
6 Months 15.54 84.46 1.76 5.9 19.29 80.71 1.25 6.3 
12 Months 16.94 83.06 1.81 5.6 23.21 76.79 1.28 6.1 
18 Months 17.84 82.16 1.85 5.4 26.40 73.60 1.29 6.0 
24 Months 18.95 81.05 1.89 5.2 29.22 70.78 1.31 5.9 
Initial Screening Age to=50 
6 Months 2.52 97.48 3.70 4.2 5.04 94.96 2.75 3.7 
12 Months 3.80 96.2 3.78 4.0 8.87 91.l3 2.76 3.6 
18 Months 5.29 94.71 3.83 3.8 12.27 87.73 2.76 3.5 
24 Months 6.89 93.11 3.88 3.6 15.40 84.6 2.77 3.5 
Initial Screening Age to=60 
6 Months 0.066 99.934 4.75 3.6 2.58 97.42 3.76 2.9 
12 Months 0.315 99.685 4.81 3.4 5.04 94.96 3.75 2.9 
18 Months 0.779 99.221 4.85 ") ") 7.39 92.61 3.72 2.9 .J . .J 
24 Months 1.47 98.53 4.90 3.2 9.64 90.36 3.71 2.8 
15 
Table 4 
A projection of the lead time distribution when mean sojourn time = 20 years 
Log-Logistic Exponential 
fj, Po I-Po EL Med Po I-Po EL Med 
Initial Screening Age to=40 
6 Months 12.53 87.47 4.32 8.1 16.44 83.56 1.14 7.1 
12 Months 13.73 86.27 4.53 7.7 19.37 80.63 1.18 6.9 
18 Months 14.47 85.53 4.71 7.4 21.70 78.30 1.21 6.7 
24 Months 15.05 84.95 4.91 7.1 23.74 76.26 1.26 6.5 
Initial Screening Age to=50 
6 Months 1.87 98.13 6.86 5.9 3.81 96.19 2.42 4.4 
12 Months 3.05 96.95 7.11 5.6 6.63 93.37 2.47 4.2 
18 Months 4.07 95.93 7.31 5.3 9.12 90.88 2.50 4.1 
24 Months 5.05 94.95 7.52 5.1 11.43 88.57 2.54 4.1 
Initial Screening Age to=60 
6 Months 0.017 99.983 8.60 4.3 1.47 98.53 3.55 3.3 
12 Months 0.078 99.922 8.72 4.3 3.09 96.91 3.56 3.3 
18 Months 0.193 99.807 7.80 4.2 4.57 95.43 3.57 3.3 
24 Months 0.366 99.634 8.93 4.1 6.01 93.99 3.58 3.3 
The following figures give the density curves for the lead time for the different 
screening intervals, sojourn times, and sojourn distributions but only for females when to 
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Figure 3. Lead time probability distributions when sojourn time distribution is 
exponential 
These results show that for a mean sojourn time (MST) of two years and a log-
logistic sojourn time distribution, an individual that begins screening at age 40 and 
receives screenings twice a year has a 28.4% chance that their cancer will not be detected 
by early screening. This value increases to 44.94% and 63.68% when screening 
frequency is decreased to once a year and twice a year, respectively. We see a similar 
trend for initial screening ages of 50 years, 8.34%, 24. 10%, and 52.71 %, and 60 years, 
18 
5.40%, 19.56%, and 46.32%, for ~ = 0.5, 1.0, and 2.0 years respectively. We find that the 
probability an individual will not experience detection by screening increases as 
screening frequency decreases when we hold MST and age constant. This probability 
decreases as age increases when holding screening frequency and MST constant, and 
decreases as MST increases with age and screening frequency held constant. 
From the graphs of the lead time distributions based on the log-logistic sojourn 
time distribution, we see that the mode, mean, and median are monotonically increasing 
as MST increases. We find the same trend for the mean and median when the sojourn 
time distribution is exponential, however, the mode when the sojourn time distribution is 
exponential is relatively constant across mean sojourn times (right around one year). We 
also find that when the MST is two or five years the mean decreases as screening 
frequency decreases, but find the opposite effect when the MST is ten or twenty years. 
Also, mean increases as age increases with MST and screening frequency being held 
constant. The trends we see in the median are that it increases as age increases (frequency 




We took the model presented by Wu, Kafadar, Roner, and Broemling, 2012 and 
derived the lead time distribution for different sets of periodic cancer screening when 
lifetime was subjected to competing causes (it was a random variable). This model 
extends Wu et al.' s previous work to include more simulations that can apply to cancers 
other than breast cancer. 
We examined the lead time distribution for two different sojourn time 
distributions: log-logistic and exponential, four different mean sojourn times: 2 years, 5 
years, 10 years, and 20 years, and four different screening frequencies: twice a year, once 
a year, once every year and a half, and every two years, for both men and women. We 
found that the outcomes were very similar for both men and women, and therefore it 
wasn't necessary to present the results for both genders. 
Gathering data from all of these simulations allows us to extend our results to 
several prevalent cancers such as breast cancer, prostate cancer, lung cancer, and 
colorectal cancer which are some of the most common cancers amongst men and/or 
women today. One study examined HIP study population, a sample from Edinburgh, and 
a sample from Canada in order to determine the mean sojourn times for each group. They 
assumed an exponentially distributed sojourn time and found the mean sojourn times to 
20 
be 2.5, 4.3, and 1.9 (ages 40-49) and 3.1 (ages 50-59), respectively (Shen & 
Zelen). Lung cancer and colorectal cancer were found to have similar mean sojourn times 
as breast cancer when assuming an exponentially distributed sojourn time. Lung cancer 
showed mean sojourn times between 1.38 and 3.86 years (Chien & Chen); proximal 
colorectal cancer gave mean sojourn times of 3.86 years for individuals aged 45 to 54 
years, 3.78 for 55 to 64 year olds, and 2.70 for 65-74 year olds; and distal colorectal 
cancer was found to have mean sojourn times of 3.35 for individuals aged 45 to 54 years, 
2.24 for 55 to 64 year olds, and 2.10 for 65 to 74 year olds (Zheng & Rutter). A doctor 
could use our results where MST is two or five years and the sojourn time distribution is 
exponential to develop an efficient screening program for individuals aged 40 to 60 years 
old who are at risk for breast cancer, lung cancer, or colorectal cancer. Another study, 
assuming an exponentially distributed sojourn time as well, found the mean sojourn time 
for prostate cancer to be 11.3 years for men aged 50 to 59 years and 12.6 years for men 
aged 60 to 69 years (Pashayan et al.). In this case, our results where MST is equal to 
either 10 or 20 years and the sojourn time distribution is exponential, could be used to 
come up with effective screening programs for males at risk for prostate cancer. 
The Greater New York Health Insurance Plan study was conducted over 50 years 
ago. Therefore, since our estimates for the transition probability distribution, sojourn time 
distribution, and sensitivity distribution were adopted from the HIP study, our results may 
not be an accurate reflection of current conditions. Also, our simulations only take age 
and gender into account as a covariate. In the future, we hope to not only get more 
accurate estimates for the aforementioned parameters and distributions, but also to 
include some other possible covariates to make our results applicable to more subgroups. 
21 
Finally, our model assumes that sensitivity and sojourn time are independent of each 
other even though there is evidence that suggests this may not be the case. In future work, 
we may want to examine this relationship more closely. 
22 
REFERENCES 
Centers for Disease Control and Prevention. (2009, January 8,2013). United States Cancer 
Statistics (USCS). Retrieved March 12, 2013, from 
http://www.cdc.gov/Features/CancerStatistics/ 
Centers for Disease Control and Prevention. (2011, December 15, 2011). Lung Cancer Screening. 
Retrieved March 12, 2013, from 
http://www.cdc.gov/cancer/lung/basicinfo/screening.htm 
Centers for Disease Control and Prevention. (2012). Breast Cancer. Retrieved February 28, 
2013, from http://www.cdc.gov/cancer/breast/.htm 
Chien, C. R., & Chen, T. H. Mean sojourn time and effectiveness of mortality reduction for lung 
cancer screening with computed tomography. International Journal of Cancer, 122(11), 
2594-2599. 
Pashayan, N., Duffy, S. W., Pharoah, P., Greenberg, D., Donovan, J., Martin, R. M., ... Neal, D. E. 
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due 
to screening with PSA: implications of sojourn time on screening. British Journal of 
Cancer, 100(7), 1198-1204. 
Prorok, Philip C. (1982). Bounded Recurrence Times and Lead Time in the Design of a Repetitive 
Screening Program. Journal of Applied Probability, 19(1), 10-19. doi: 10.2307/3213911 
Shen, Y., & Zelen, M. Screening sensitivity and sojourn time from breast cancer early detection 
clinical trials: mammograms and physical examinations. Journal of Clinical Oncology, 
19(15), 3490-3499. 
23 
Social Security Administration. (2012, 2012). Actuarial Life Table. Retrieved February 28, 2013, 
from http://wWw.socialsecurity.gOV/OACT/STATS/table4c6.html 




Wu, D., Kafadar, K., Rosner, G. L., & Broemeling, L. D. (2012). The lead time distribution when 
lifetime is subject to competing risks in cancer screening. tnt J Biostat, 8(1). doi: 
10.1515/1557-4679.1363 
Wu, D., Rosner, G. L., & Broemeling, L. (2005). MLE and Bayesian inference of age-dependent 
sensitivity and transition probability in periodic screening. Biometrics, 61(4), 1056-1063. 
doi: 10.1111/j.1541-0420.2005.00361.x 
Wu, D., Rosner, G. L., & Broemeling, L. D. (2007). Bayesian inference for the lead time in periodic 
cancer screening. Biometrics, 63(3), 873-880. 
ZELEN, M., & FEINLEIB, M. (1969). On the theory of screening for chronic diseases. Biometrika, 
56(3), 601-614. doi: 1O.1093/biomet/56.3.601 
Zheng, W., & Rutter, C. M. Estimated mean sojourn time associated with hemoccult SENSA for 
detection of proximal and distal colorectal cancer. Cancer Epidemiology, Biomarkers & 




909 Cannons Lane Louisville, KY 40207 
502-259-8766 skkend01@louisville.edu 
Education 
Bachelor of Arts in Mathematics; Minor in Chemistry, May 2010 
Wittenberg University, OH 
Masters of Science in Biostatistics, May 2013 
University of Louisville, KY 
Honors 
Member, Alpha Lambda Delta Honor Society 2006-2007 
Recipient, Departmental Scholarship Spring 2012 
Member, Deans List, Wittenberg University and University of Louisville 
Member, Kentucky Public Health Association 20 12-Present 
Work Experience 
Research Assistant, University of Louisville, Louisville KY, January 2012-present 
Tutor, University of Louisville School of Public Health and Information Sciences, 
Louisville, KY Fall 2011 
Personal Assistant, Street Moda, Louisville, KY July 2011-January 2012 
Customer Service Attendant, Kohl's Department Store, Jeffersonville, IN August 2010-
July 2011 
Work Study, Wittenberg University, Springfield, OH February 2008-May 2010 
Nanny, Prospect, KY, 2007-2010 Summers 
Retail Associate, Quest Outdoors, Louisville, KY July 2005-December 2009 
25 
Volunteer Work 
Family Allergy and Asthma; intern; Louisville, KY; summer 2009 
Community Hospital Pediatric Unit; Springfield, OH; 2008 
Mercy Hospital Pharmacy; Springfield, OH; 2007 
Big Brothers Big Sisters of Kentuckiana, 2004-2006 
Skills 
Technical: Proficient in Microsoft Word, Excel, and PowerPoint; Extensive experience 
using Internet and Email including Microsoft Internet Explorer, Google Chrome, and 
Mozilla Firefox; proficient in statistical software such as SAS, R, and S-Plus. 
Communication: Proficient in oral and written communication. 
26 
